|Last Price||Today's Change||52-Week Range||Trading Volume|
|92.83||1.47 (+1.61%)||66.29 - 93.35||2.7 million (Above Avg)|
Market data as of 12:42PM 08/20/14. Quotes are delayed by at least 15 min.
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate
08/19/2014 7:30 AM ET
Celgene Reports Second Quarter 2014 Operating and Financial Results
07/24/2014 7:30 AM ET